
Opinion|Videos|May 17, 2024
RCC: Informing Treatment Decisions with Clinical Trial Data
Experts on renal cell carcinoma discuss how clinical trial data inform treatment decisions, highlighting the negative results from PROSPER, CheckMate 914 Part A, and IMmotion010.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
2
Daraxonrasib Shows Antitumor Activity in RAS-Mutant NSCLC
3
G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC
4
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
5































